Johnson & Johnson (JNJ) MedTech Chairman Tim Schmid acknowledged competitive pressure in the electrophysiology (EP) market, particularly in international and Asia-Pacific markets including China. He anticipates China's volume-based procurement (VBP) program will eventually affect the EP market, potentially later this year and into 2027, and plans to add one meaningful pulsed field ablation (PFA) catheter annually for the next three to five years.